Santa Rosa, CA, USA, June 11, 2026 (GLOBE NEWSWIRE) -- FDA Breakthrough Device Designation Granted for XGal-3, an Investigational Apheresis Device Designed to Target Galectin-3 in Sepsis Patients ...
Santa Rosa, United States, June 25th, 2026, FinanceWireEliaz Therapeutics Announces Publication Highlighting Selective ...
Terumo Blood and Cell Technologies (Terumo BCT) is teaming up with Eliaz Therapeutics Inc. to develop and commercialize a new type of apheresis treatment for acute kidney injury (AKI) and ...
FDA Breakthrough Device Designation Granted for XGal-3, an Investigational Apheresis Device Designed to Target Galectin-3 in Sepsis Patients Eliaz Therapeutics, Inc., a clinical-stage medical device ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results